ID OLIG2_HUMAN Reviewed; 323 AA. AC Q13516; B3KRF3; Q05BP9; Q49AL3; Q86X04; Q9NZ14; DT 30-MAY-2000, integrated into UniProtKB/Swiss-Prot. DT 13-AUG-2002, sequence version 2. DT 27-MAR-2024, entry version 183. DE RecName: Full=Oligodendrocyte transcription factor 2; DE Short=Oligo2; DE AltName: Full=Class B basic helix-loop-helix protein 1; DE Short=bHLHb1; DE AltName: Full=Class E basic helix-loop-helix protein 19; DE Short=bHLHe19; DE AltName: Full=Protein kinase C-binding protein 2; DE AltName: Full=Protein kinase C-binding protein RACK17; GN Name=OLIG2; Synonyms=BHLHB1, BHLHE19, PRKCBP2, RACK17; OS Homo sapiens (Human). OC Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia; OC Eutheria; Euarchontoglires; Primates; Haplorrhini; Catarrhini; Hominidae; OC Homo. OX NCBI_TaxID=9606; RN [1] RP NUCLEOTIDE SEQUENCE [MRNA]. RC TISSUE=Hippocampus; RA Kuroda S., Tokunaga C., Kiyohara Y., Konishi H., Kikkawa U.; RT "Protein kinase C-binding protein."; RL Submitted (FEB-1996) to the EMBL/GenBank/DDBJ databases. RN [2] RP NUCLEOTIDE SEQUENCE [MRNA], AND CHROMOSOMAL TRANSLOCATION. RX PubMed=10737801; DOI=10.1073/pnas.97.7.3497; RA Wang J., Jani-Sait S.N., Escalon E.A., Carroll A.J., de Jong P.J., RA Kirsch I.R., Aplan P.D.; RT "The t(14;21)(q11.2;q22) chromosomal translocation associated with T-cell RT acute lymphoblastic leukemia activates the BHLHB1 gene."; RL Proc. Natl. Acad. Sci. U.S.A. 97:3497-3502(2000). RN [3] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=14702039; DOI=10.1038/ng1285; RA Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R., RA Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H., RA Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S., RA Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K., RA Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A., Sudo H., RA Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M., Takahashi M., RA Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y., Abe K., Kamihara K., RA Katsuta N., Sato K., Tanikawa M., Yamazaki M., Ninomiya K., Ishibashi T., RA Yamashita H., Murakawa K., Fujimori K., Tanai H., Kimata M., Watanabe M., RA Hiraoka S., Chiba Y., Ishida S., Ono Y., Takiguchi S., Watanabe S., RA Yosida M., Hotuta T., Kusano J., Kanehori K., Takahashi-Fujii A., Hara H., RA Tanase T.-O., Nomura Y., Togiya S., Komai F., Hara R., Takeuchi K., RA Arita M., Imose N., Musashino K., Yuuki H., Oshima A., Sasaki N., RA Aotsuka S., Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S., RA Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O., RA Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H., RA Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B., RA Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y., Fujimori Y., RA Komiyama M., Tashiro H., Tanigami A., Fujiwara T., Ono T., Yamada K., RA Fujii Y., Ozaki K., Hirao M., Ohmori Y., Kawabata A., Hikiji T., RA Kobatake N., Inagaki H., Ikema Y., Okamoto S., Okitani R., Kawakami T., RA Noguchi S., Itoh T., Shigeta K., Senba T., Matsumura K., Nakajima Y., RA Mizuno T., Morinaga M., Sasaki M., Togashi T., Oyama M., Hata H., RA Watanabe M., Komatsu T., Mizushima-Sugano J., Satoh T., Shirai Y., RA Takahashi Y., Nakagawa K., Okumura K., Nagase T., Nomura N., Kikuchi H., RA Masuho Y., Yamashita R., Nakai K., Yada T., Nakamura Y., Ohara O., RA Isogai T., Sugano S.; RT "Complete sequencing and characterization of 21,243 full-length human RT cDNAs."; RL Nat. Genet. 36:40-45(2004). RN [4] RP NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA]. RC TISSUE=Brain; RX PubMed=15489334; DOI=10.1101/gr.2596504; RG The MGC Project Team; RT "The status, quality, and expansion of the NIH full-length cDNA project: RT the Mammalian Gene Collection (MGC)."; RL Genome Res. 14:2121-2127(2004). RN [5] RP TISSUE SPECIFICITY. RX PubMed=11498220; DOI=10.1016/s0140-6736(01)05499-x; RA Marie Y., Sanson M., Mokhtari K., Leuraud P., Kujas M., Delattre J.-Y., RA Poirier J., Zalc B., Hoang-Xuan K.; RT "OLIG2 as a specific marker of oligodendroglial tumour cells."; RL Lancet 358:298-300(2001). RN [6] RP TISSUE SPECIFICITY. RX PubMed=11526205; DOI=10.1073/pnas.181340798; RA Lu Q.R., Park J.K., Noll E., Chan J.A., Alberta J.A., Yuk D.-I., RA Alzamora M.G., Louis D.N., Stiles C.D., Rowitch D.H., Black P.M.; RT "Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial RT brain tumors."; RL Proc. Natl. Acad. Sci. U.S.A. 98:10851-10856(2001). CC -!- FUNCTION: Required for oligodendrocyte and motor neuron specification CC in the spinal cord, as well as for the development of somatic motor CC neurons in the hindbrain. Functions together with ZNF488 to promote CC oligodendrocyte differentiation. Cooperates with OLIG1 to establish the CC pMN domain of the embryonic neural tube. Antagonist of V2 interneuron CC and of NKX2-2-induced V3 interneuron development. CC {ECO:0000250|UniProtKB:Q9EQW6}. CC -!- SUBUNIT: Interacts with NKX2-2. Interacts with ZNF488. CC {ECO:0000250|UniProtKB:Q9EQW6}. CC -!- INTERACTION: CC Q13516; P60329: KRTAP12-4; NbExp=3; IntAct=EBI-3914525, EBI-10176396; CC Q13516; P40222: TXLNA; NbExp=3; IntAct=EBI-3914525, EBI-359793; CC -!- SUBCELLULAR LOCATION: Nucleus {ECO:0000255|PROSITE-ProRule:PRU00981}. CC Cytoplasm {ECO:0000250}. Note=The NLS contained in the bHLH domain CC could be masked in the native form and translocation to the nucleus CC could be mediated by interaction either with class E bHLH partner CC protein or with NKX2-2. {ECO:0000250}. CC -!- TISSUE SPECIFICITY: Expressed in the brain, in oligodendrocytes. CC Strongly expressed in oligodendrogliomas, while expression is weak to CC moderate in astrocytomas. Expression in glioblastomas highly variable. CC {ECO:0000269|PubMed:11498220, ECO:0000269|PubMed:11526205}. CC -!- INDUCTION: By SHH. Also induced by NKX6-1 in the developing spinal CC cord, but not in the rostral hindbrain (By similarity). {ECO:0000250}. CC -!- DOMAIN: The bHLH is essential for interaction with NKX2-2. CC {ECO:0000250}. CC -!- DISEASE: Note=A chromosomal aberration involving OLIG2 may be a cause CC of a form of T-cell acute lymphoblastic leukemia (T-ALL). Translocation CC t(14;21)(q11.2;q22) with TCRA. {ECO:0000269|PubMed:10737801}. CC -!- SEQUENCE CAUTION: CC Sequence=AAC72247.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC Sequence=AAF61215.1; Type=Erroneous initiation; Evidence={ECO:0000305}; CC -!- WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and CC Haematology; CC URL="https://atlasgeneticsoncology.org/gene/236/OLIG2"; CC --------------------------------------------------------------------------- CC Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms CC Distributed under the Creative Commons Attribution (CC BY 4.0) License CC --------------------------------------------------------------------------- DR EMBL; U48250; AAC72247.1; ALT_INIT; mRNA. DR EMBL; AF221520; AAF61215.1; ALT_INIT; mRNA. DR EMBL; AK091462; BAG52365.1; -; mRNA. DR EMBL; BC034681; AAH34681.1; -; mRNA. DR EMBL; BC036245; AAH36245.1; -; mRNA. DR EMBL; BC047511; AAH47511.1; -; mRNA. DR CCDS; CCDS13620.1; -. DR PIR; G02409; G02409. DR RefSeq; NP_005797.1; NM_005806.3. DR RefSeq; XP_005260965.1; XM_005260908.1. DR AlphaFoldDB; Q13516; -. DR SMR; Q13516; -. DR BioGRID; 115510; 11. DR IntAct; Q13516; 12. DR STRING; 9606.ENSP00000331040; -. DR iPTMnet; Q13516; -. DR PhosphoSitePlus; Q13516; -. DR BioMuta; OLIG2; -. DR DMDM; 22261817; -. DR MassIVE; Q13516; -. DR PaxDb; 9606-ENSP00000331040; -. DR PeptideAtlas; Q13516; -. DR Antibodypedia; 917; 622 antibodies from 41 providers. DR DNASU; 10215; -. DR Ensembl; ENST00000333337.3; ENSP00000331040.3; ENSG00000205927.5. DR Ensembl; ENST00000382357.4; ENSP00000371794.3; ENSG00000205927.5. DR GeneID; 10215; -. DR KEGG; hsa:10215; -. DR MANE-Select; ENST00000382357.4; ENSP00000371794.3; NM_005806.4; NP_005797.1. DR UCSC; uc002yqx.3; human. DR AGR; HGNC:9398; -. DR CTD; 10215; -. DR DisGeNET; 10215; -. DR GeneCards; OLIG2; -. DR HGNC; HGNC:9398; OLIG2. DR HPA; ENSG00000205927; Tissue enriched (brain). DR MIM; 606386; gene. DR neXtProt; NX_Q13516; -. DR OpenTargets; ENSG00000205927; -. DR PharmGKB; PA31919; -. DR VEuPathDB; HostDB:ENSG00000205927; -. DR eggNOG; KOG3898; Eukaryota. DR GeneTree; ENSGT00940000161651; -. DR HOGENOM; CLU_065376_1_0_1; -. DR InParanoid; Q13516; -. DR OMA; GMPCPCN; -. DR OrthoDB; 5324482at2759; -. DR PhylomeDB; Q13516; -. DR TreeFam; TF322733; -. DR PathwayCommons; Q13516; -. DR SignaLink; Q13516; -. DR SIGNOR; Q13516; -. DR BioGRID-ORCS; 10215; 18 hits in 1171 CRISPR screens. DR GeneWiki; OLIG2; -. DR GenomeRNAi; 10215; -. DR Pharos; Q13516; Tbio. DR PRO; PR:Q13516; -. DR Proteomes; UP000005640; Chromosome 21. DR RNAct; Q13516; Protein. DR Bgee; ENSG00000205927; Expressed in inferior vagus X ganglion and 76 other cell types or tissues. DR ExpressionAtlas; Q13516; baseline and differential. DR GO; GO:0000785; C:chromatin; ISA:NTNU_SB. DR GO; GO:0005737; C:cytoplasm; IEA:UniProtKB-SubCell. DR GO; GO:0005634; C:nucleus; IBA:GO_Central. DR GO; GO:0000981; F:DNA-binding transcription factor activity, RNA polymerase II-specific; ISA:NTNU_SB. DR GO; GO:0070888; F:E-box binding; IBA:GO_Central. DR GO; GO:0071837; F:HMG box domain binding; IEA:Ensembl. DR GO; GO:0042802; F:identical protein binding; IEA:Ensembl. DR GO; GO:0046983; F:protein dimerization activity; IEA:InterPro. DR GO; GO:1990837; F:sequence-specific double-stranded DNA binding; IDA:ARUK-UCL. DR GO; GO:0061564; P:axon development; IBA:GO_Central. DR GO; GO:0042552; P:myelination; IEA:Ensembl. DR GO; GO:0045665; P:negative regulation of neuron differentiation; IEA:Ensembl. DR GO; GO:0000122; P:negative regulation of transcription by RNA polymerase II; IEA:Ensembl. DR GO; GO:0048663; P:neuron fate commitment; IEA:Ensembl. DR GO; GO:0048714; P:positive regulation of oligodendrocyte differentiation; IEA:Ensembl. DR GO; GO:0045944; P:positive regulation of transcription by RNA polymerase II; IBA:GO_Central. DR GO; GO:0007423; P:sensory organ development; IBA:GO_Central. DR GO; GO:0021522; P:spinal cord motor neuron differentiation; IEA:Ensembl. DR GO; GO:0021530; P:spinal cord oligodendrocyte cell fate specification; IEA:Ensembl. DR GO; GO:0021794; P:thalamus development; IEA:Ensembl. DR CDD; cd18940; bHLH_TS_OLIG2; 1. DR Gene3D; 4.10.280.10; Helix-loop-helix DNA-binding domain; 1. DR InterPro; IPR011598; bHLH_dom. DR InterPro; IPR036638; HLH_DNA-bd_sf. DR InterPro; IPR032658; Olig2_bHLH. DR PANTHER; PTHR19290; BASIC HELIX-LOOP-HELIX PROTEIN NEUROGENIN-RELATED; 1. DR PANTHER; PTHR19290:SF32; OLIGODENDROCYTE TRANSCRIPTION FACTOR 2; 1. DR Pfam; PF00010; HLH; 1. DR SMART; SM00353; HLH; 1. DR SUPFAM; SSF47459; HLH, helix-loop-helix DNA-binding domain; 1. DR PROSITE; PS50888; BHLH; 1. DR Genevisible; Q13516; HS. PE 1: Evidence at protein level; KW Chromosomal rearrangement; Cytoplasm; Developmental protein; DNA-binding; KW Nucleus; Proto-oncogene; Reference proteome; Transcription; KW Transcription regulation. FT CHAIN 1..323 FT /note="Oligodendrocyte transcription factor 2" FT /id="PRO_0000127414" FT DOMAIN 108..162 FT /note="bHLH" FT /evidence="ECO:0000255|PROSITE-ProRule:PRU00981" FT REGION 1..107 FT /note="Disordered" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 28..48 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT COMPBIAS 73..95 FT /note="Polar residues" FT /evidence="ECO:0000256|SAM:MobiDB-lite" FT CONFLICT 67 FT /note="G -> V (in Ref. 3; AAH36245)" FT /evidence="ECO:0000305" FT CONFLICT 150 FT /note="A -> T (in Ref. 4; AAH47511)" FT /evidence="ECO:0000305" SQ SEQUENCE 323 AA; 32385 MW; 0EC9223961062509 CRC64; MDSDASLVSS RPSSPEPDDL FLPARSKGSS GSAFTGGTVS SSTPSDCPPE LSAELRGAMG SAGAHPGDKL GGSGFKSSSS STSSSTSSAA ASSTKKDKKQ MTEPELQQLR LKINSRERKR MHDLNIAMDG LREVMPYAHG PSVRKLSKIA TLLLARNYIL MLTNSLEEMK RLVSEIYGGH HAGFHPSACG GLAHSAPLPA ATAHPAAAAH AAHHPAVHHP ILPPAAAAAA AAAAAAAVSS ASLPGSGLPS VGSIRPPHGL LKSPSAAAAA PLGGGGGGSG ASGGFQHWGG MPCPCSMCQV PPPHHHVSAM GAGSLPRLTS DAK //